Cormorant Asset Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Cormorant Asset Management’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,188,659	Closed	-$2.74M	–	69
2023 Q2	$2.74M	Hold	9,188,659	–	–	0.15%	57
2023 Q1	$3.97M	Hold	9,188,659	–	–	0.26%	51
2022 Q4	$10.8M	Sell	9,188,659 -1,072,901	-10%	-$1.75M	0.73%	36
2022 Q3	$23.8M	Buy	10,261,560 +3,301,020	+47%	+$8.64M	1.66%	22
2022 Q2	$15.2M	Buy	6,960,540 +250,000	+4%	+$1.73M	1.15%	30
2022 Q1	$62M	Buy	+6,710,540	New	+$60.1M	4.76%	5

Cormorant Asset Management's GRNA Position: Q3 2023 in Review

Cormorant Asset Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 9,188,659 shares — an estimated $2.74M sold.

Cormorant Asset Management first reported a position in GRNA in Q1 2022 and held it in 6 quarters. The position peaked at $62M in Q1 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Cormorant Asset Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Cormorant Asset Management sold 9,188,659 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $2.74M.
Cormorant Asset Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 6 quarters.
Cormorant Asset Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $62M in Q1 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Cormorant Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.